Clinical Trial: Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07458659) titled 'Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma' on Feb. 26.

Brief Summary: A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma.

Study Start Date: June 01, 2026

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Multiple Myeloma (MM)

Intervention: BIOLOGICAL: Chimeric Antigen Receptor T Cells (CAR-T)

This product is a CAR T-cell therapy utilizing the participant's own autologous T-lymphocytes, which are collected via apheresis, processed...